Status:
COMPLETED
Virtual Reality Mediated Upper Extremity rehabilitationPatients With Cerebral Palsy
Lead Sponsor:
Istanbul University
Collaborating Sponsors:
The Scientific and Technological Research Council of Turkey
Conditions:
Cerebral Palsy
Upper Extremity Paresis
Eligibility:
All Genders
5-12 years
Phase:
NA
Brief Summary
Cerebral palsy (CP) refers to a group of permanent disorders that occur in the brain of the fetus or infant, which are non-progressive, cause movement and posture disorder along with activity limitati...
Detailed Description
Cerebral Palsy (CP) is a group of permanent disorders of movement and posture development due to non-progressive damage to the developing fetal or infant brain, causing activity limitation. Motor diso...
Eligibility Criteria
Inclusion
- Having been diagnosed with hemiplegic CP by a specialist pediatric neurologist,
- Being between the ages of 5-12,
- Following the child's simple commands and participating in the given tasks,
- Being at the Gross Motor Function Classification System (KMFSS) Stage 1, 2 or 3,
- Being in Hand Skills Classification System (MACS) Stage 1, 2 or 3,
- Mild / moderate muscle tone; Modified Ashworth Scale level 1-2 and Tardieu Scale level 1-2,
- Parents agree to participate in the intensive treatment program and to cease all other upper extremity therapeutic interventions during the 3-month follow-up period.
Exclusion
- Having uncontrollable epileptic seizures
- Significant contractures in the fingers, wrists, elbows and shoulders that prevent daily activities,
- Having serious vision and hearing problems,
- Cognitive impairments that prevent understanding and performing simple commands and tasks,
- Not being able to continue the treatment protocol due to the school program,
- Current or previous treatments that are not compatible with the treatment protocol of the study,
- Orthopedic surgery (tendon transfer / tendon lengthening) applied to the upper extremity,
- Receiving upper extremity treatment within the last 6 months (BTX-A or orthopedic interventions),
- Uncontrolled disease (endocrinological, cardiovascular, pulmonary, hematological, hepatic, renal), active systemic inflammatory disease and / or history of malignancy
Key Trial Info
Start Date :
August 20 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04529343
Start Date
August 20 2020
End Date
December 30 2020
Last Update
March 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ahmet Kıvanç Menekşeoğlu
Istanbul, Turkey (Türkiye), 34015